Text Size
18 studies found for:    "microbicide" AND "gel" | Open Studies | HIV

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Recruiting Safety of Acidform Lubricant in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Acidform Lubricant;   Drug: HEC gel
2 Recruiting Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
Condition: HIV Prevention
Interventions: Drug: Tenofovir gel;   Drug: Universal placebo gel
3 Recruiting Microbicide Safety and Acceptability in Young Men
Conditions: High Risk MSM;   HIV Negative;   18-30 Years of Age
Interventions: Other: HEC Placebo Gel;   Drug: Tenofovir 1% Gel
4 Recruiting Tenofovir Gel in Pregnancy and Lactation
Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel;   Other: Placebo gel
5 Recruiting A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel;   Drug: Universal HEC Placebo Gel Formulation
6 Recruiting An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulation (VF) of tenofovir 1% gel;   Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel;   Radiation: Radiolabeling of study drugs and semen
7 Recruiting Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
8 Not yet recruiting Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
9 Unknown † An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: HIV Infections
Intervention: Drug: HEC placebo gel
10 Not yet recruiting Biomarkers of Protocol Compliance and Product Adherence
Condition: HIV Prevention
Intervention: Other: HEC placebo gel applicators
11 Recruiting Assessing the Safety of Dapivirine Gel and Film Formulations
Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film;   Drug: Dapivirine Vaginal Gel
12 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
13 Not yet recruiting Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV
Interventions: Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet);   Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel);   Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
14 Not yet recruiting In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% gel;   Drug: Vaginal product
15 Recruiting Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
16 Unknown † A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Condition: HIV Infection
Intervention: Drug: Different formulations of once-daily lopinavir/ritonavir
17 Recruiting KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
Condition: Antiretroviral Therapy in HIV-1 Infected Children
Interventions: Drug: Kaletra dosed once daily;   Drug: kaletra dosed twice daily
18 Unknown † Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
To Top

† Indicates status has not been verified in more than two years